Zobrazeno 1 - 10 of 55 pro vyhledávání: '"Boris Shor"'
1
Akademický článek
The BCG Vaccine for COVID-19: First Verdict and Future Directions
Autor: Maria Gonzalez-Perez, Rodrigo Sanchez-Tarjuelo, Boris Shor, Estanislao Nistal-Villan, Jordi Ochando
Publikováno v: Frontiers in Immunology, Vol 12 (2021)
Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world popu
Externí odkaz: https://doaj.org/article/88379c8891d240549097190cda747931
Zobrazit plný text záznamu
2
Elektronická kniha
Red State, Blue State, Rich State, Poor State : Why Americans Vote the Way They Do - Expanded Edition
Autor: Andrew Gelman, Boris Shor, Jeronimo Cortina, David K. Park
On the night of the 2000 presidential election, Americans watched on television as polling results divided the nation's map into red and blue states. Since then the color divide has become symbolic of a culture war that thrives on stereotypes—picku
Zobrazit plný text záznamu
3
Supplementary Figures and Tables from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Autor: Puja Sapra, Eugene Melamud, Fang Wang, Ed Rosfjord, Michelle Mack, Jane Xu, Maureen Dougher, Jennifer Kahler, Boris Shor
Supplementary Figures S1-S6. Supplementary Figure S1. 5T4 protein expression in selected preclinical models. Supplementary Figure S2. Effects of MMAF-Ome combined with PF-384. Supplementary Figure S3. Effect of PF-384 combination with auristatin-base
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5d20cabe304dd95a83cd7d3e76e954e7
https://doi.org/10.1158/1078-0432.22458924
Zobrazit plný text záznamu
4
Data from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Autor: Puja Sapra, Eugene Melamud, Fang Wang, Ed Rosfjord, Michelle Mack, Jane Xu, Maureen Dougher, Jennifer Kahler, Boris Shor
Purpose: Targeted treatment of solid or liquid tumors with antibody–drug conjugates (ADCs) can lead to promising clinical benefit. The aim of the study is to investigate combination regimens of auristatin-based ADCs in preclinical models of cancer.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aca3828eb968cef2e4ce5e9fab2a5c62
https://doi.org/10.1158/1078-0432.c.6524079
Zobrazit plný text záznamu
5
Supplementary Information from Enhanced Antitumor Activity of an Anti-5T4 Antibody–Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes
Autor: Puja Sapra, Eugene Melamud, Fang Wang, Ed Rosfjord, Michelle Mack, Jane Xu, Maureen Dougher, Jennifer Kahler, Boris Shor
Supplementary Methods to complete the information for cellular assays in vitro and protein identification by mass spectrometry. The file also contains legends for supplementary figures S1-S6 and supplementary tables S1-S3.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12607ced277673ac9969261ca806e99b
https://doi.org/10.1158/1078-0432.22458921
Zobrazit plný text záznamu
8
Data from A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein Synthesis
Autor: Ker Yu, James J. Gibbons, Robert T. Abraham, Jessica Lucas, Lourdes Toral-Barza, Wei-Guo Zhang, Boris Shor
The mammalian target of rapamycin (mTOR) inhibitor CCI-779 (temsirolimus) is a recently Food and Drug Administration–approved anticancer drug with efficacy in certain solid tumors and hematologic malignancies. In cell culture studies, CCI-779 at th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37d797566ed5815a77bb617368267ad0
https://doi.org/10.1158/0008-5472.c.6497649
Zobrazit plný text záznamu
10
The BCG Vaccine for COVID-19: First Verdict and Future Directions
Autor: Maria Gonzalez-Perez, Rodrigo Sanchez-Tarjuelo, Boris Shor, Estanislao Nistal-Villan, Jordi Ochando
Publikováno v: Frontiers in Immunology
Repisalud
Instituto de Salud Carlos III (ISCIII)
Frontiers in Immunology, Vol 12 (2021)
Despite of the rapid development of the vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses and the proper infrastructure to vaccinate a good proportion of the world popu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8131ba78af33c7c6f70ba85a9204ff92
https://pubmed.ncbi.nlm.nih.gov/33763077
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje